Dec 14, 2020 7:00am EST VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
Dec 09, 2020 6:55am EST Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer
Dec 09, 2020 6:30am EST Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results
Nov 23, 2020 8:30am EST Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th
Sep 29, 2020 8:30am EDT Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer
Sep 18, 2020 7:30am EDT Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer
Sep 09, 2020 8:30am EDT Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences
Aug 18, 2020 8:30am EDT Veru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product
Aug 04, 2020 8:30am EDT VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19
